Atrion Co. (NASDAQ:ATRI) Director John P. Stupp, Jr. sold 277 shares of the stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $711.47, for a total transaction of $197,077.19. Following the completion of the sale, the director now directly owns 5,844 shares in the company, valued at $4,157,830.68. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
ATRI opened at $706.26 on Friday. The business has a fifty day moving average of $763.53 and a 200 day moving average of $795.23. Atrion Co. has a 52-week low of $671.05 and a 52-week high of $948.03. The stock has a market cap of $1.31 billion, a P/E ratio of 36.01 and a beta of 0.14.
Atrion (NASDAQ:ATRI) last announced its quarterly earnings data on Friday, November 1st. The medical instruments supplier reported $5.15 EPS for the quarter. Atrion had a return on equity of 16.45% and a net margin of 23.43%. The company had revenue of $38.88 million for the quarter.
Several brokerages have issued reports on ATRI. ValuEngine upgraded Atrion from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. BidaskClub cut Atrion from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 19th.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Krane Funds Advisors LLC purchased a new position in Atrion in the 2nd quarter worth about $57,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Atrion during the 3rd quarter valued at about $79,000. Quantamental Technologies LLC boosted its position in Atrion by 5,000.0% in the 2nd quarter. Quantamental Technologies LLC now owns 102 shares of the medical instruments supplier’s stock valued at $87,000 after buying an additional 100 shares during the period. Russell Investments Group Ltd. purchased a new stake in Atrion in the 3rd quarter valued at about $88,000. Finally, Cubist Systematic Strategies LLC bought a new position in Atrion in the 2nd quarter worth about $256,000. Hedge funds and other institutional investors own 66.08% of the company’s stock.
Atrion Company Profile
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Featured Article: Neutral Rating
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.